BLU-5937 is a Small Molecule owned by BELLUS Health, and is involved in 8 clinical trials, of which 5 were completed, and 3 are ongoing.
BLU-5937 (NEO-5937) is P2X3 receptor antagonist. P2X3 ligand-gated ion channel may transduce ATP-evoked nociceptor activation. The drug candidate binds to the P2X3 receptor and blocks ATP-mediated hypersensitivity in primary afferents, thereby reducing visceral pain and improving the symptoms of PBS/IC.
The revenue for BLU-5937 is expected to reach a total of $607m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BLU-5937 NPV Report.
BLU-5937 (NEO-5937) is under development for the treatment of chronic refractory cough and and other cough hypersensitization-related disorders. The drug candidate is a benzoimidazole derivative, formulated as a tablet and is administered through oral route. The drug candidate targets P2X purinoceptor 3 (P2X3) receptor. It was also under development for interstitial cystitis (PBS/IC), osteoarthritis pain, visceral pain and chronic pruritus associated with atopic dermatitis.
BELLUS Health Overview
BELLUS Health is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics for treating patients with chronic cough and hypersensitization-related disorders. The company’s lead product, BLU-593 (formerly NEO5937) is a potent, orally bio-available, highly selective small-molecule antagonist of the P2X3 receptor which is being developed for treating refractory chronic cough, and chronic pruritus associated with atopic dermatitis. It has license agreement and collaborations with NEOMED institute for the development and commercialization of BLU-593. The company operates in Canada and the US through its subsidiaries. BELLUS Health is headquartered in Laval, Quebec, Canada.
The operating loss of the company was US$73.3 million in FY2021, compared to an operating loss of US$32.9 million in FY2020. The net loss of the company was US$71.2 million in FY2021, compared to a net loss of US$31.8 million in FY2020.
Quick View – BLU-5937
|Highest Development Stage|